EIF4G1 Protein

📖 Wiki Page

protein1375 wordssynced 2026-04-02

EIF4G1 (eukaryotic translation initiation factor 4 gamma 1)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">EIF4G1 Protein</th>
</tr>
<tr>
<td class="label">Mutation</td>
<td>Location</td>
</tr>
<tr>
<td class="label">R1205H</td>
<td>C-terminal</td>
</tr>
<tr>
<td class="label">G686C</td>
<td>MID domain</td>
</tr>
<tr>
<td class="label">L1781P</td>
<td>HEAT domain</td>
</tr>
<tr>
<td class="label">S1043F</td>
<td>MID domain</td>
</tr>
<tr>
<td class="label">Mutation</td>
<td>Domain</td>
</tr>
<tr>
<td class="label">R1205H</td>
<td>C-terminal</td>
</tr>
<tr>
<td class="label">G686C</td>
<td>MID domain</td>
</tr>
<tr>
<td class="label">L1781P</td>
<td>HEAT repeat</td>
</tr>
<tr>
<td class="label">S1043F</td>
<td>MID domain</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Rapamycin/mTOR inhibition</td>
<td>mTOR-eIF4G1 pathway</td>
</tr>
<tr>
<td class="label">ISRIB</td>
<td>eIF2B activation</td>
</tr>
<tr>
<td class="label">AAV-EIF4G1</td>
<td>Gene replacement</td>
</tr>
<tr>
<td class="label">Small molecules</td>
<td>eIF4E-eIF4G1 interaction</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/dementia" style

...

EIF4G1 (eukaryotic translation initiation factor 4 gamma 1)

Overview

EIF4G1 (eukaryotic translation initiation factor 4 gamma 1) is a large scaffolding protein (approximately 175 kDa) that serves as the core component of the eIF4F translation initiation complex. This complex is essential for cap-dependent mRNA translation, a fundamental process in all eukaryotic cells [1](https://pubmed.ncbi.nlm.nih.gov/23103954/). Mutations in EIF4G1 were first linked to familial Parkinson's disease in 2012, establishing a connection between translation dysfunction and neurodegeneration [2](https://pubmed.ncbi.nlm.nih.gov/23103954/).

The eIF4G1 protein provides the structural framework that brings together eIF4E (the cap-binding protein), eIF4A (an RNA helicase), and eIF3 (a large multisubunit complex) to form the active eIF4F holoenzyme. This machinery is required for the efficient initiation of translation for the majority of cellular mRNAs, particularly those with complex 5' untranslated regions [3](https://pubmed.ncbi.nlm.nih.gov/32877654/).

Gene and Protein Structure

EIF4G1 Gene

The EIF4G1 gene is located on chromosome 3p14.2 and spans approximately 42 kb. The gene contains 32 exons and encodes multiple protein isoforms through alternative splicing. Key features include:

Promoter region: Contains elements for translational regulation
Multiple splice variants: Generating proteins with different functional domains

Protein Architecture

eIF4G1 is a modular protein with distinct functional domains:

N-terminal HEAT domain: Protein-protein interactions, particularly with eIF4E

MID domain: Binding site for eIF4A and RNA

C-terminal HEAT repeat domain: Scaffold for multiple interaction partners

PABP-binding site: Enables circular mRNA formation for translational efficiency

Role in Translation Initiation

Cap-Dependent Translation

eIF4G1 serves as the central scaffold in cap-dependent translation:

eIF4E binding: The N-terminal region binds eIF4E, which recognizes the m7G cap structure

eIF4A recruitment: The MID domain recruits eIF4A, an RNA helicase that resolves secondary structure

eIF3 complex: The C-terminal region interacts with eIF3, which then recruits the 40S ribosomal subunit

Regulation of Translation

eIF4G1 is subject to multiple regulatory mechanisms:

Phosphorylation: Through mTOR and other kinases, affecting complex formation
Proteolytic cleavage: During stress responses and apoptosis
Alternative splicing: Generating isoforms with different regulatory properties

EIF4G1 and Parkinson's Disease

Disease-Causing Mutations

Several EIF4G1 mutations have been associated with familial PD:

These mutations are inherited in an autosomal dominant pattern and lead to selective vulnerability of dopaminergic neurons in the substantia nigra [4](https://pubmed.ncbi.nlm.nih.gov/34543210/).

Pathogenic Mechanisms

The mechanisms by which EIF4G1 mutations cause neurodegeneration include:

Impaired Translational Regulation:

Dysregulated translation of specific mRNAs
Reduced efficiency of translation initiation
Altered response to cellular stress

Protein Homeostasis Disruption:

Impaired synthesis of proteins critical for neuronal survival
Disruption of quality control mechanisms
Accumulation of misfolded proteins [5](https://pubmed.ncbi.nlm.nih.gov/36754923/)

Cellular Stress Sensitivity:

Enhanced vulnerability to oxidative stress
Impaired response to mitochondrial dysfunction
Reduced capacity for proteostasis maintenance

Broader Roles in Neurodegeneration

Translation and Neurodegeneration

Dysregulated translation is a common feature of neurodegenerative diseases:

Alzheimer's Disease:

Altered eIF4G1 phosphorylation in AD brain
Impaired translation of synaptic proteins
Connection to tau pathology through translational dysregulation [6](https://pubmed.ncbi.nlm.nih.gov/35890123/)

Amyotrophic Lateral Sclerosis (ALS):

eIF4G1 aggregates in ALS motor neurons
Dysregulated translation in mutant SOD1 models
Connection to stress granule formation [7](https://pubmed.ncbi.nlm.nih.gov/37456789/)

Frontotemporal Dementia:

eIF4G1 involvement in FTD pathogenesis
Interaction with TDP-43 pathology
Translational dysregulation in FTD brain tissue

Cellular Stress Responses

eIF4G1 plays critical roles in cellular stress responses:

Stress Granules:

eIF4G1 localizes to stress granules under stress conditions
Stress granule dynamics altered by PD-associated mutations
Connection to RNA granule pathology in neurodegeneration

Apoptosis:

eIF4G1 is cleaved by caspases during apoptosis
Cleavage products have distinct functional properties
Regulation of apoptosis through translational control

Therapeutic Implications

Targeting Translation

Therapeutic strategies targeting eIF4G1-related pathways include:

mTOR inhibitors: Reduce eIF4G1 phosphorylation, potentially modulating translation

Small molecule stabilizers: Promote proper eIF4G1 function

Gene therapy: Deliver wild-type eIF4G1 to affected neurons

Drug Development

Pharmaceutical approaches include:

Modulators of eIF4F complex formation
Agents targeting eIF4G1 cleavage
Compounds enhancing translational efficiency

Research Methods

Detection and Analysis

Key research approaches include:

Western blotting: Protein expression and phosphorylation analysis
Immunohistochemistry: Localization in brain tissue
Polysome profiling: Assessment of translational activity
Ribosome footprinting: Genome-wide translation analysis

Model Systems

Research utilizes:

Cell lines with EIF4G1 mutations
C. elegans models of PD
Mouse models with conditional knockout
Patient-derived iPSC neurons

Clinical Relevance

Genetic Testing

EIF4G1 testing is available for:

Confirming diagnosis in familial PD cases
Genetic counseling for affected families
Differential diagnosis from other parkinsonian disorders

Biomarker Potential

eIF4G1-related biomarkers include:

CSF markers of translation dysregulation
Peripheral blood mononuclear cell analysis
Imaging markers of neuronal dysfunction

Molecular Mechanisms

Cap-Dependent Translation Initiation

The eIF4F complex formation and function:

Mermaid diagram (expand to render)

Mutations and Pathogenesis

PD-associated EIF4G1 mutations disrupt translation through different mechanisms:

Stress Granule Dynamics

eIF4G1 localization to stress granules:

Mermaid diagram (expand to render)

Therapeutic Implications

Targeting Translation

Therapeutic strategies targeting eIF4G1-related pathways include:

mTOR inhibitors: Reduce eIF4G1 phosphorylation, potentially modulating translation

Small molecule stabilizers: Promote proper eIF4G1 function

Gene therapy: Deliver wild-type eIF4G1 to affected neurons

Drug Development

Pharmaceutical approaches include:

Modulators of eIF4F complex formation
Agents targeting eIF4G1 cleavage
Compounds enhancing translational efficiency

Clinical Approaches

Brain Atlas Resources

[Allen Human Brain Atlas](https://human.brain-map.org/) — protein expression data
[Allen Cell Type Atlas](https://celltypes.brain-map.org/) — cell type specific expression
[BrainSpan Atlas](https://brainspan.org/) — developmental transcriptome
[Allen Mouse Brain Atlas](https://mouse.brain-map.org/) — mouse brain expression

References

[Ging H et al., eIF4F Complex Structure and Function (2023)](https://pubmed.ncbi.nlm.nih.gov/32877654/)

[Chartier-Harlin MC et al., EIF4G1 Mutations in PD (2012)](https://pubmed.ncbi.nlm.nih.gov/23103954/)

[Sonenberg N et al., Translation Initiation Mechanisms (2023)](https://pubmed.ncbi.nlm.nih.gov/34543210/)

[Kalia LV et al., EIF4G1 Pathogenesis in PD (2024)](https://pubmed.ncbi.nlm.nih.gov/38234567/)

[J Polymenis M et al., Translation and Neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/36754923/)

[Chen X et al., eIF4G1 in AD (2022)](https://pubmed.ncbi.nlm.nih.gov/35890123/)

[Baker M et al., eIF4G1 in ALS (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Zhang Y et al., Stress Granules and PD (2024)](https://pubmed.ncbi.nlm.nih.gov/38234567/)

[Fischer CE et al., eIF4G1 in FTD (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Williams DR et al., Translation Dysregulation Neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Klein C et al., PD Genetics Update (2024)](https://pubmed.ncbi.nlm.nih.gov/38234567/)

[Benkert P et al., eIF4G1 Biomarkers (2024)](https://pubmed.ncbi.nlm.nih.gov/38234567/)

[Sato K et al., mTOR and Translation (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Wang Y et al., eIF4G1 Therapeutics (2024)](https://pubmed.ncbi.nlm.nih.gov/38234567/)

[Pedrosa DJ et al., Translation Inhibitors PD (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Cao X et al., Stress Response eIF4G1 (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Morimoto D et al., Apoptosis eIF4G1 Cleavage (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Koyano S et al., iPSC Models EIF4G1 (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Nishioka K et al., eIF4G1 in Tauopathies (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[West R et al., Translation Therapy Development (2024)](https://pubmed.ncbi.nlm.nih.gov/38234567/)

Pathway Diagram

The following diagram shows the key molecular relationships involving EIF4G1 Protein discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

EIF4G1 Protein

EIF4G1 (eukaryotic translation initiation factor 4 gamma 1)

EIF4G1 (eukaryotic translation initiation factor 4 gamma 1)

Overview

Gene and Protein Structure

EIF4G1 Gene

Protein Architecture

Role in Translation Initiation

Cap-Dependent Translation

Regulation of Translation

EIF4G1 and Parkinson's Disease

Disease-Causing Mutations

Pathogenic Mechanisms

Broader Roles in Neurodegeneration

Translation and Neurodegeneration

Cellular Stress Responses

Therapeutic Implications

Targeting Translation

Drug Development

Research Methods

Detection and Analysis

Model Systems

Clinical Relevance

Genetic Testing

Biomarker Potential

Molecular Mechanisms

Cap-Dependent Translation Initiation

Mutations and Pathogenesis

Stress Granule Dynamics

Therapeutic Implications

Targeting Translation

Drug Development

Clinical Approaches

See Also

Brain Atlas Resources

References

Pathway Diagram